Chr. Hansen reports “higher than expected” organic growth …

Danish bioscience business Chr. Hansen has ended the first half of its financial year with 11% organic growth driven by both volume and price increases. (Image Credit: Chr. Hansen). 13 Apr 2023 — Danish bioscience business Chr. Hansen has ended the first half of its financial year with 11% organic growth driven by both volume and price increases. Its “lighthouses,” strategic business areas with a minimum revenue potential of €100 million (US$97.2 million), delivered 38% growth in Q2 “positively impacted by the timing of orders,” according to the company. Chr. Hansen has five lighthouses – Bioprotection, Fermented Plant Bases, Plant Health, HMO (Human Milk Oligosaccharides) and Bacthera, which outpaced the general business growth – delivering 38% organic growth in Q2, compared to 8% of the core businesses. Nonetheless, even after achieving double-digit organic growth, Lise Mortensen, CFO at Chr. Hansen tells NutritionInsight that the company “remains cautious” in their “volume expectation for the full year, given the macroeconomic and geopolitical uncertainties.” “On inflation, a better-than-anticipated winter combined with declining transportation costs has impacted our cost outlook positively. This is unfortunately offset by higher than expected price increases in other categories (direct materials including certain raw materials, packaging, etc.), reflecting a delayed impact from last year’s inflation and continued bottlenecks in supply,” she continues.